Replimune’s twice-rejected melanoma drug prevails in FDA adcomm
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Replimune’s twice-rejected melanoma drug prevails in FDA adcomm" is generating significant coverage in the Business category, with 2 articles from 2 distinct sources tracked by PULSE so far.
Outlets currently covering the story include WSJ and FirstWord Pharma. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 88d ago.
Quick answers
Why is "Replimune’s twice-rejected melanoma drug prevails in FDA adcomm" trending?
Because 2 independent news sources published 2 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (2)
- Opinion WSJ · 91d ago
- Replimune's oncolytic immunotherapy clears FDA panel despite trial flaws FirstWord Pharma · 91d ago
Topics
Related trends
US Health Secretary RFK Jr to expand access to unapproved peptides
US Health Secretary RFK Jr. faces scientist pushback after greenlighting access to unapproved wellness peptides.
Peptide peddlers cheer as RFK Jr. unilaterally grants access, overruling FDA
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
RFK Jr. plans to make 6 unapproved peptides available for temporary sale
RFK Jr. plans to bypass FDA regulations to allow the temporary sale of six unapproved peptides, sparking reactions from industry proponents.
Kennedy to Allow Broad Use of Unapproved Peptide Injections
Health Secretary Kennedy faces scientific opposition after opening broad access to unapproved peptide injections.
FDA scientists opposed the Trump administration’s effort to ease peptides access
Trump administration moves to loosen U.S. rules on unapproved peptides as FDA scientists push back, sparking a split in medical and political circles.
FDA offers new details on quicker approval pathway for personalized gene therapies
Federal regulators release new guidance detailing a quicker approval pathway for personalized gene therapies.